Search Results
Aug 25, 2026, 08:44 ET Fosun Pharma Announces 2026 Interim Results
progressing in international multi-center trials across China, the US, Europe, Australia, Japan and other geographies. As a potential best-in-class pan-tumor PD-L1-targeting ADC, HLX43 has demonstrated promising preliminary clinical efficacy featuring high potency and favorable safety profiles across multiple
More news about: Fosun Pharma
Aug 25, 2026, 06:15 ET Innovent Announces 2026 Interim Results and Business Updates
malignancies. Focusing on the next-generation "IO + ADC" innovation strategy, the Company is advancing next-generation assets including IBI363 (PD-1/IL-2α-biased), IBI343 (CLDN18.2 ADC), and IBI3003 (GPRC5D/BCMA/CD3) into late-stage clinical development, establishing long-term growth drivers and competitive
More news about: Innovent Biologics
Aug 24, 2026, 20:30 ET Antengene Receives Clinical Trial Approval in Australia for Phase I ATTRACT Study of ATG-201 (CD19 x CD3 TCE) in B Cell-related Autoimmune Diseases
commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs developed using
More news about: Antengene Corporation Limited
Aug 24, 2026, 09:00 ET Behavior experts offer solutions for students who need intensive support
Global PD Teams and
More news about: Solution Tree
Aug 24, 2026, 08:10 ET Leading Parkinson's Organizations Outline Priorities for the National Plan Ahead of Advisory Council Meeting
Parkinson Disease Association (APDA) is a nonprofit organization dedicated to fighting Parkinson's disease (PD) by providing the support, education, research, and community that helps everyone impacted by PD live life to the fullest. Through a nationwide grassroots network of Chapters and Information &
More news about: Parkinson's Foundation
Aug 24, 2026, 05:27 ET American Parkinson Disease Association Launches Spanish-Language Microsite, Expanding Support for Underserved Parkinson's Community
serve.The new Spanish-language microsite features:Comprehensive information about PD, including symptoms, diagnosis, treatment options, and moreGuidance for living well with PD focused on nutrition, exercise, mental health, therapies, and other topicsEducational webinars
More news about: American Parkinson Disease Association, Inc.
Aug 23, 2026, 21:00 ET Antengene Announces 2026 Interim Results: Achieves First‑Ever Profitability and Accelerates Value Creation Through Innovative R&D
ATG-125 (B7-H3 x PD-L1 bispecific ADC): ATG-125 is an "IO + ADC" dual-function molecule targeting B7-H3 and PD-L1, integrating the direct cytotoxic activity of an ADC with the durable immune activation of IO therapies. By simultaneously blocking B7-H3- and PD-L1-mediated immunosuppressive
More news about: Antengene Corporation Limited
Aug 23, 2026, 20:00 ET Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
human clinical development into new indications."ABT-301 is currently being evaluated in a Phase I/II clinical trial in combination with anti-PD-1 and anti-VEGF in patients with pMMR/non-MSI-High metastatic colorectal cancer. As an isoform-selective Class I HDACi, ABT-301 is designed to modulate
More news about: AnBogen Therapeutics
Aug 23, 2026, 20:00 ET Anbogen Therapeutics and The University of Tokyo Enter Collaborative Research Agreement to Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
human clinical development into new indications."ABT-301 is currently being evaluated in a Phase I/II clinical trial in combination with anti-PD-1 and anti-VEGF in patients with pMMR/non-MSI-High metastatic colorectal cancer. As an isoform-selective Class I HDACi, ABT-301 is designed to modulate
More news about: AnBogen Therapeutics
Aug 21, 2026, 16:20 ET Robbins LLP Urges REPL Investors Who Lost Money Investing in Replimune to Contact the Firm for Information About Leading the Class Action
Biologics License Application ("BLA") for RP1 in combination with nivolumab for the treatment of advanced melanoma in patients who progress on an anti-PD-1 containing regimen. The Company claimed that "[a]dditional information, data and analyses were included in the resubmission which will be part of the
More news about: Robbins LLP
Aug 21, 2026, 08:58 ET Henlius Reports 2026 Interim Results: Sustained Profitability Leap, Advancing Global Value Validation, and Accelerating Progress Towards C-MNC
first anti–PD-1 mAb approved for first-line treatment of small cell lung cancer and for perioperative gastric cancer. Up to date, it has been approved in 50 markets worldwide with an accelerated globalisation process. In parallel, multiple high-potential innovative assets—including the PD-L1 ADC HLX43
More news about: Henlius
Aug 21, 2026, 08:08 ET CureGene Completes First‑Participant Dose in Phase I Trial of CG‑0416, Advancing Clinical Development of Novel Oral Liver-Targeting THR-β Agonist
double-blind, placebo-controlled study in healthy participants, designed to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of CG-0416 following single and multiple ascending doses. Leveraging Australia's well-established Phase I clinical infrastructure, this trial will generate
More news about: CureGene
Aug 21, 2026, 07:45 ET AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
NCT06772623). The study is evaluating a platinum-free combination of Temab-A and a PD-1 inhibitor, as a potential first-line treatment for advanced non-squamous NSCLC. The study includes analyses of c-Met and PD-L1 expression to identify the patients most likely to benefit from treatment.3 Temab-A
More news about: AbbVie
Aug 21, 2026, 05:20 ET Leads Biolabs' Opamtistomig (PD-L1/4-1BB Bispecific Antibody) NDA Accepted by NMPA, Poised to Become World's First Approved 4-1BB-Targeting Therapy
(NDA) for Opamtistomig (LBL-024), the Company's proprietary PD-L1/4-1BB bispecific antibody, as a monotherapy for the treatment of previously treated advanced extrapulmonary neuroendocrine carcinoma (EP-NEC). Opamtistomig is the first PD-L1/4-1BB bispecific antibody globally to enter NDA review
More news about: Nanjing Leads Biolabs Co., Ltd.
Aug 21, 2026, 03:24 ET 3S Bio Announces 2026 Interim Results: Innovation-Driven, Win-Win Collaboration, and Sustainable Growth
disease. 705 (anti-PD-1/HER2 bispecific antibody) has entered Phase II clinical trials for HER2-positive solid tumors, standing as the only drug with this target actively advancing in clinical stages in China, demonstrating significant differentiation. 706 (anti-PD-1/PD-L1 bispecific antibody) has
More news about: 3SBio Inc.
Aug 20, 2026, 19:10 ET 騰盛博藥發佈最新公司業務進展及2026中期業績報告
BRII-5395是騰盛博藥自主開發的一款新型mRNA治療性疫苗，目前正作為免疫治療方案的一部分，在HBV相關HCC患者中開展臨床評估。2026年8月12日（報告期後），一項評估BRII-5395用於晚期HCC患者的臨床研究完成首例患者給藥。該研究在中國醫學科學院腫瘤醫院開展，旨在評估BRII-5395聯合抗-PD-1抗體和抗-VEGF抗體的安全性、耐受性、免疫原性及初步抗腫瘤活性。當前作為標準治療的免疫檢查點抑制劑對HCC的療效仍存在局限性。作為騰盛博藥首個進入臨床評估階段的自主研發mRNA癌症治療性疫苗，BRII-5395是公司推進內部發現能力和基於RNA的技術平
More news about: 騰盛博藥生物科技有限公司
Aug 20, 2026, 19:10 ET Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results
Sciences, is designed to evaluate the safety, tolerability, immunogenicity and preliminary anti-tumor activity of BRII-5395 in combination with an anti-PD-1 antibody and an anti-VEGF antibody. The current standard of care of immune checkpoint inhibitors have limited efficacy
More news about: Brii Biosciences Limited
Aug 20, 2026, 14:20 ET The Lustgarten Foundation Announces New Pancreatic Cancer Research Funding Totaling $22.8 Million In Fiscal Year 2026
MD, Mass General Brigham Cancer Institute, for his study "A phase 2 trial of a novel Fc enhanced CTLA4 antibody, Vilastobart, in combination with PD-1 inhibitor, Retifanlimab, in BRCA/PALB2 mutated pancreatic cancers." Singh's team will investigate a novel immunotherapy combination for patients
More news about: Lustgarten Foundation
Aug 20, 2026, 12:00 ET Silkland Launches the First 1.5-Meter Passive Thunderbolt 5 Cable to Market
80Gbps bidirectional bandwidth, 240W USB PD 3.1 EPR, Intel certified - as of August 2026, the first available to consumers, exclusively at silklandtech.comNEW YORK, Aug. 20, 2026
More news about: Silkland
Aug 20, 2026, 09:00 ET Curriculum and Teacher PD Come Together as One Partner for School Districts
curriculum and instructional design powered by CSA Education, and AI-enabled data intelligence powered by Abl Insights and Digital Flex—offering an HQIM-PD Full-Stack Education Ecosystem.About CSA Education Founded in 1989, CSA Education is a K-12 curriculum company that provides
More news about: BetterLesson Learning
Aug 20, 2026, 08:00 ET Inspīr Embassy Row Partners with The Washington Ballet to Bring Dance and Art Experiences to Residents
arts community.The partnership will also introduce Dance for Parkinson's Disease (Dance for PD®), a program designed for people living with Parkinson's disease. Through music and movement, Dance for PD® supports mobility, confidence, creative expression and social connection.Classes at Inspīr
More news about: Maplewood Senior Living
Aug 20, 2026, 03:00 ET CUKTECH Highlights Four Charging Essentials for Back-to-School Season in the Middle East
with 55W fast charging. Its built-in dual-cable design reduces the need to carry extra cables, while three-device charging and support for SCP, UFCS and PD protocols provide compatibility across multiple devices.For lighter everyday carry and outdoor activities, the CUKTECH CP13 is a 10,000mAh
More news about: CUKTECH
Aug 19, 2026, 10:31 ET Checkpoint Inhibitor Refractory Cancer Market Outlook is Predicted to Improve by 2036, Biopharma Companies Advance Novel Immuno-Oncology Candidates | DelveInsight
PD-1 and PD-L1 Inhibitors Competitive LandscapePD-1 and PD-L1 Inhibitors Competitive Landscape – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 and PD-L1 inhibitors
More news about: DelveInsight Business Research, LLP
Aug 19, 2026, 09:41 ET Sensorium Therapeutics Announces SNTX-2643 Phase 1a Data to Be Presented at Psych Congress 2026
from Sensorium's ongoing Phase 1a study of SNTX-2643 in healthy adults evaluating its safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profile. The study includes single-ascending dose, exploratory qEEG target engagement/pharmacodynamic and food-effect cohorts. The target engagement
More news about: Sensorium Therapeutics
Aug 18, 2026, 21:00 ET Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit
across different lines of gastric cancer treatment, including first-line therapy in combination with anti-PD-1 antibodies and chemotherapy (CAPOX/FOLFOX); second-line therapy in combination with anti-PD-1 antibodies; and third-line therapy as monotherapy. In addition, the CLINCH study of ATG-022 includes
More news about: Antengene Corporation Limited